HTG Expands Patent Portfolio with New Canadian Patent for its Nuclease Protection Methods for Detection of Nucleotide Variants
Share: TUCSON, Ariz., Dec. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for "Nuclease Protection Methods for Detection of Nucleotide Variants." The patented technology involves a nuclease protection method using wildtype and variant probes competing for binding to a target nucleic acid molecule, such as messenger RNA, to detect the presence, if any, of a variant nucleotide in the target...
Source: benzinga.com